Investors Press Releases Jan 04 2023 Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer Read More Jan 03 2023 Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab Read More Dec 29 2022 Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Updated Interim Results for the Six Months Ended 30 June 2022 Read More btn News View All Events & Presentations Jan 09 2023 - Jan 11 2023 Jan 09 2023 - Jan 11 2023 Biotech Showcase Read More Dec 29 2022 Dec 29 2022 Annual General Meeting 2022 Read More Nov 10 2022 at 10:00 AM EST Nov 10 2022 at 10:00 AM EST Investor call Read More btn Events View All Interim Reports Interim Results for the Six Months Ended 30 June 2022 641.6 KB bth Interim Reports View All Annual Reports 20 F - Annual Report for the year ended 31 December 2021 1.9 MB btn ARs View All Annual General Meeting Notice of Annual General Meeting December 2022 276.9 KB btn AGM View All Scientific Pipeline Progress Learn more × Stock Quote Change Volume Today's Open Previous Close Today's High Today's Low 52 Week High 52 Week Low Stock Chart
Jan 04 2023 Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer Read More
Jan 03 2023 Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab Read More
Dec 29 2022 Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Updated Interim Results for the Six Months Ended 30 June 2022 Read More